Other
Recurrent or Metastatic
0
Pipeline Programs↗
12
Active Trials↗
9
Companies Involved↗
Recurrent or Metastatic is an early-stage landscape with 0 programs across 9 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., Eli Lilly, AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
40
clinical trials
Completed17 · 43%
Recruiting9 · 23%
Unknown status6 · 15%
Terminated4 · 10%
Active, not recruiting3 · 8%
Suspended1 · 3%
Clinical Trials
Trial Activity
40 trials
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT04713046·24 enrolled
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
Completed·—·Phase 2·NCT04811027·171 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)